CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 enrolled
Drug / intervention
cisplatin +1 moredrug
Likely dose
cisplatin 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00691301
NCT00691301Phase 2Completed
CompareCT.gov

A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix

Gynecologic Oncology Group·interventional·Posted Jun 5, 2008·Updated Jan 9, 2018

In Brief

A Phase 2 clinical trial evaluating cisplatin and pemetrexed disodium for Cervical Cancer. Completed, enrolled 55 participants across 12 sites.

Detailed Summary

RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pemetrexed together with cisplatin may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects of giving pemetrexed together with cisplatin and to see how well it works in treating patients with advanced, persistent, or recurrent cervical cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 5, 2008
Enrollment StartSep 1, 2008
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 18.1 years ago

Interventions

cisplatindrug

Cisplatin as an IV infusion at less than 1 mg/min over less than 4 hours at a dose of

pemetrexed disodiumdrug